跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AB-10
首页
药物
AB-10
AB-10
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Enzymatic conversion of blood group a,b, and ab red blood cells using alpha-n-acetylgalactosaminidases and alpha-galactosidases with unique substrate specificities and kinetic properties
US 7767415 B2
申请人: VELICO MEDICAL INC
优先权: 2002
EP
US
9 件公开
MODIFIED ADENOVIRUSES
EP 3737403 B1
申请人: UNIV COLLEGE CARDIFF CONSULTANTS LTD
优先权: 2018
CN
EP
US
WO
6 件公开
Antibody-conjugates for targeting of tumours expressing PTK7
US 12440573 B2
申请人: SYNAFFIX BV
优先权: 2022
CN
EP
US
WO
6 件公开
PATCH SHEET FOR SKIN, USE OF THE SAME, ULTRAVIOLET SENSING METHOD, AND METHOD FOR EVALUATING ULTRAVIOLET PROTECTION PERFORMANCE
EP 4227654 B1
申请人: KAO CORP
优先权: 2020
CN
EP
US
WO
5 件公开
IMMUNOCONJUGATES TARGETING EGFR
EP 3843789 A1
申请人: BOLT BIOTHERAPEUTICS INC
优先权: 2018
CN
EP
US
WO
4 件公开
METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE
EP 4088739 A4
申请人: EISAI R&D MAN CO LTD
优先权: 2019
CN
EP
US
WO
4 件公开
ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2
EP 4496594 A1
申请人: SYNAFFIX BV
优先权: 2022
CN
EP
US
WO
4 件公开
ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING CARCINOEMBYRONIC ANTIGEN
EP 4496595 A1
申请人: SYNAFFIX BV
优先权: 2022
CN
EP
US
WO
4 件公开
GLYCAN-CONJUGATED ANTIBODIES BINDING TO FC-GAMMA RECEPTOR
EP 4267195 A1
申请人: SYNAFFIX BV
优先权: 2020
EP
US
WO
3 件公开
ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING NECTIN-4
EP 4496593 A1
申请人: SYNAFFIX BV
优先权: 2022
EP
US
WO
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈